The Global Breast Cancer Screening Crisis: How Liquid Biopsies Can Bridge the Divide
Scottland’s NHS has raised concerns about the future of its NHS breast cancer screening program.
BIOMARK Announces Warrant Extension and Granting of Options
BIOMARK Announces Warrant Extension and Granting of Options Vancouver, British Columbia – (April 18th, 2024) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce that the Company intends to amend […]
BIOMARK TO ADVANCE DEVELOPMENT OF CANCER TREATMENT FOR GLIOBLASTOMA
BIOMARK TO ADVANCE DEVELOPMENT OF CANCER TREATMENT FOR GLIOBLASTOMA The Company secured collaborative research funding from Research Manitoba and Mitacs for an animal proof-of-concept study. Vancouver, British Columbia – (April 9, 2024) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus […]
BIOMARK PartnerS with RUBIX LS to Advance Blood-based Cancer Screening in Underserved Communities
Vancouver, British Columbia – (February 28, 2024) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers and Rubix LS, a culturally competent patient medical research organization, jointly announce today the signature of a strategic […]
Theresa Peterson Joins BioMark’s Advisory Team
Vancouver, British Columbia – (February 26, 2024) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX, FSE: 20B, OTCMKTS: BMKDF) an advanced-stage liquid biopsy company with a focus on hard-to-detect and treat cancers is pleased to announce that Mrs. Theresa Peterson as a new member of BioMark’s Advisory team. Mr. Rashid Ahmed Bux, CEO and President of […]
BIOMARK ANNOUNCES CLOSING OF $1.9 MILLION NON-BROKERED PRIVATE PLACEMENT
BIOMARK ANNOUNCES CLOSING OF $1.9 MILLION NON-BROKERED PRIVATE PLACEMENT Vancouver, British Columbia – (December 29th, 2023) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today that it has closed […]
insightscare Interview: BioMark Diagnostics Inc: Innovating Cancer Detection
BioMark Diagnostics Inc: Innovating Cancer Detection From the interview originally published by insightscare https://insightscare.com/biomark-diagnostics-inc-innovating-cancer-detection/ Rashid A Bux | CEO and Founder | BioMark Diagnostics Inc A dynamic field like diagnostics requires efficient technologies for detecting diseases and critical illnesses. One organization that stands out with its innovative solutions in pursuit of this universal mission is BioMark […]
BIOMARK ANNOUNCES RECENT NEW PATENT GRANTED IN CANADA TO SUPPORT ITS LIQUID BIOPSY BASED LEGACY ASSAY
BIOMARK ANNOUNCES RECENT NEW PATENT GRANTED IN CANADA TO SUPPORT ITS LIQUID BIOPSY BASED LEGACY ASSAY Vancouver, British Columbia – (December 4th, 2023) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) a clinical and diagnostic laboratory developing a liquid biopsy molecular diagnostic tests with a focus on hard to […]
BIOMARK PROVIDES SECOND QUARTER OPERATIONAL UPDATE AND ANNOUNCES EXTENSION TO WARRANT EXERCISE TERM
BIOMARK PROVIDES SECOND QUARTER OPERATIONAL UPDATE AND ANNOUNCES EXTENSION TO WARRANT EXERCISE TERM Vancouver, British Columbia – (November 28th, 2023) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers today reports strong operational results […]